Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:29AM ET
1.58
Dollar change
+0.10
Percentage change
6.75
%
IndexRUT P/E- EPS (ttm)-1.25 Insider Own8.15% Shs Outstand114.92M Perf Week11.26%
Market Cap181.80M Forward P/E- EPS next Y-1.01 Insider Trans-2.70% Shs Float105.69M Perf Month18.79%
Income-143.10M PEG- EPS next Q-0.33 Inst Own66.39% Short Float21.89% Perf Quarter71.08%
Sales146.03M P/S1.24 EPS this Y1.62% Inst Trans-0.05% Short Ratio13.16 Perf Half Y15.32%
Book/sh-1.19 P/B- EPS next Y17.66% ROA-47.81% Short Interest23.13M Perf Year-54.99%
Cash/sh1.67 P/C0.95 EPS next 5Y- ROE- 52W Range0.62 - 4.87 Perf YTD82.65%
Dividend Est.- P/FCF- EPS past 5Y16.79% ROI-381.58% 52W High-67.56% Beta0.02
Dividend TTM- Quick Ratio3.32 Sales past 5Y52.21% Gross Margin96.25% 52W Low155.90% ATR (14)0.14
Dividend Ex-Date- Current Ratio3.37 EPS Y/Y TTM38.32% Oper. Margin-88.71% RSI (14)61.94 Volatility6.81% 11.47%
Employees325 Debt/Eq- Sales Y/Y TTM-7.03% Profit Margin-97.99% Recom1.57 Target Price5.57
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q14.88% Payout- Rel Volume0.70 Prev Close1.48
Sales Surprise-4.68% EPS Surprise-16.13% Sales Q/Q0.50% EarningsFeb 29 BMO Avg Volume1.76M Price1.58
SMA2013.50% SMA5028.28% SMA20027.17% Trades Volume417,797 Change6.75%
Date Action Analyst Rating Change Price Target Change
Jan-19-23Initiated Piper Sandler Overweight $8
Nov-04-22Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $10
Feb-09-22Upgrade JP Morgan Underweight → Neutral $8
Nov-19-21Resumed Morgan Stanley Equal-Weight $27 → $10
Aug-06-21Downgrade SVB Leerink Outperform → Mkt Perform $6
Aug-06-21Downgrade RBC Capital Mkts Outperform → Sector Perform $17 → $8
Aug-06-21Downgrade JP Morgan Overweight → Neutral
Jul-02-20Initiated Morgan Stanley Overweight $34
Mar-04-20Initiated Barclays Overweight $30
Jan-17-20Downgrade Wedbush Outperform → Neutral
Mar-06-24 04:05PM
Mar-04-24 11:53PM
Mar-01-24 04:05PM
09:21AM
Feb-29-24 10:03PM
06:15PM Loading…
06:15PM
08:40AM
07:50AM
07:30AM
Feb-25-24 01:37PM
Feb-22-24 07:00AM
Feb-14-24 10:00AM
Feb-01-24 04:05PM
Jan-08-24 08:30AM
Jan-03-24 07:00AM
04:05PM Loading…
Jan-02-24 04:05PM
Dec-13-23 08:47PM
Dec-10-23 08:15PM
Dec-06-23 04:00AM
Dec-01-23 04:05PM
Nov-08-23 04:05PM
Nov-06-23 07:00AM
Nov-03-23 12:46PM
Nov-02-23 03:30PM
09:33AM
09:20AM
07:47AM
07:30AM
Oct-30-23 08:00AM
Oct-26-23 07:00AM
04:05PM Loading…
Oct-02-23 04:05PM
Sep-26-23 07:00AM
Sep-05-23 04:05PM
Sep-01-23 04:05PM
08:00AM
Aug-17-23 08:44AM
Aug-03-23 02:18PM
Aug-02-23 02:00PM
08:45AM
07:37AM
07:30AM
Aug-01-23 04:05PM
Jul-26-23 07:00AM
Jul-25-23 03:00PM
Jul-19-23 08:00AM
Jul-17-23 04:05PM
Jul-05-23 04:05PM
12:00PM
Jun-28-23 08:00AM
Jun-08-23 07:40AM
Jun-01-23 04:05PM
07:00AM
May-23-23 04:05PM
May-09-23 02:59PM
May-05-23 06:07AM
May-04-23 04:09PM
01:00PM
08:55AM
07:51AM
07:45AM
May-03-23 08:46AM
May-01-23 04:10PM
04:05PM
10:01AM
Apr-27-23 10:03AM
Apr-18-23 01:30PM
Apr-17-23 07:05AM
Apr-14-23 12:00PM
Apr-03-23 04:05PM
Mar-14-23 05:36PM
Mar-08-23 07:00AM
Mar-05-23 08:48AM
Mar-01-23 04:05PM
Feb-21-23 08:00AM
Feb-16-23 06:39PM
Feb-15-23 02:00PM
08:45AM
07:30AM
Feb-09-23 10:01AM
07:00AM
Feb-08-23 07:00AM
Feb-07-23 10:00AM
Feb-01-23 04:05PM
Jan-09-23 08:00AM
Jan-04-23 07:00AM
Jan-03-23 04:05PM
Dec-12-22 07:00AM
Dec-05-22 08:30AM
08:30AM
Dec-01-22 04:05PM
Nov-08-22 09:55AM
07:00AM
Nov-04-22 12:00AM
Nov-03-22 07:35PM
09:18AM
Nov-01-22 04:05PM
07:40AM
Oct-31-22 04:35PM
Oct-25-22 09:47AM
Oct-20-22 04:05PM
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paulson Richard A.President and CEOMar 05 '24Sale1.303,5734,6451,160,836Mar 06 04:14 PM
Paulson Richard A.President and CEOMar 01 '24Sale1.2019,37423,2491,164,409Mar 04 07:36 PM
Mason MichaelEVP, CFO & TreasurerMar 01 '24Sale1.206,1627,394398,756Mar 04 07:39 PM
Poulton StuartEVP, Chief Development OfficerMar 01 '24Sale1.206,1557,386329,511Mar 04 07:40 PM
Rangwala ReshmaEVP & Chief Medical OfficerMar 01 '24Sale1.205,9697,163349,720Mar 04 07:41 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerMar 01 '24Sale1.205,1096,131393,509Mar 04 07:37 PM
Mano MichaelSVP, General Counsel&SecretaryMar 01 '24Sale1.203,5764,291277,852Mar 04 07:38 PM
Paulson Richard A.President and CEOFeb 29 '24Sale1.1780,47094,1501,183,783Mar 04 07:36 PM
Mason MichaelEVP, CFO & TreasurerFeb 29 '24Sale1.1727,68732,394404,918Mar 04 07:39 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerFeb 29 '24Sale1.1721,84025,553398,618Mar 04 07:37 PM
Mano MichaelSVP, General Counsel&SecretaryFeb 29 '24Sale1.1716,97319,858281,428Mar 04 07:38 PM
Poulton StuartEVP, Chief Development OfficerFeb 29 '24Sale1.1716,31119,084335,666Mar 04 07:40 PM
Rangwala ReshmaEVP & Chief Medical OfficerFeb 29 '24Sale1.1715,66718,330355,689Mar 04 07:41 PM
Mason MichaelEVP, CFO & TreasurerFeb 27 '24Sale1.322,5453,369244,400Feb 29 05:35 PM
Poulton StuartEVP, Chief Development OfficerFeb 15 '24Sale1.335,8477,783163,772Feb 20 04:59 PM
Mason MichaelEVP, CFO & TreasurerFeb 06 '24Sale1.594,2056,671246,945Feb 08 04:36 PM
Paulson Richard A.President and CEOFeb 06 '24Sale1.594,0126,365821,453Feb 08 04:34 PM
Paulson Richard A.President and CEOJan 04 '24Sale0.824,1143,373783,465Jan 08 09:00 PM
Paulson Richard A.President and CEODec 04 '23Sale0.793,6222,861787,579Dec 05 05:03 PM
Paulson Richard A.President and CEONov 06 '23Sale0.923,6063,319791,201Nov 07 05:32 PM
Paulson Richard A.President and CEOOct 04 '23Sale1.273,5894,558794,807Oct 05 04:46 PM
BOHLIN GAREN GDirectorSep 12 '23Buy1.2241,14049,98545,140Sep 12 04:07 PM
Paulson Richard A.President and CEOSep 05 '23Sale1.333,6224,817798,396Sep 06 04:06 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerSep 01 '23Sale1.337,4159,872204,086Sep 05 04:27 PM
Mason MichaelEVP, CFO & TreasurerSep 01 '23Sale1.336,9139,203237,817Sep 05 04:30 PM
Mano MichaelSVP, General Counsel&SecretarySep 01 '23Sale1.333,8885,176142,234Sep 05 04:29 PM
Paulson Richard A.President and CEOAug 07 '23Sale1.723,7226,402802,018Aug 08 05:02 PM
Poulton StuartEVP, Chief Development OfficerJul 28 '23Sale1.702,8454,836156,286Aug 01 05:37 PM
Paulson Richard A.President and CEOJul 05 '23Sale1.723,5386,085805,740Jul 06 05:36 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerJun 08 '23Sale2.351,8394,322211,501Jun 12 04:07 PM
Paulson Richard A.President and CEOJun 05 '23Sale2.243,5367,922809,278Jun 07 04:11 PM
Mason MichaelEVP, CFO & TreasurerJun 02 '23Sale2.226311,401244,730Jun 05 04:10 PM
Paulson Richard A.President and CEOMay 04 '23Sale3.353,80512,753812,814May 05 05:06 PM
Rangwala ReshmaEVP & Chief Medical OfficerApr 20 '23Sale4.056,77027,416158,230Apr 24 06:09 PM
Paulson Richard A.President and CEOApr 04 '23Sale3.973,49713,883816,619Apr 05 05:06 PM